Podcast
ADC Manufacturing: How Smart CDMO Selection Drives Speed, Safety, and Scale
“The complexity is there’s an antibody component, linker-payloads with highly potent toxic agents that need high containment, and linking a biologic with a highly potent small molecule – it’s inherently challenging.” Dr. Harch Ooi, VP of Manufacturing and Chemistry at
15 October 2025